Bionano Genomics (BNGO) investor relations material

Executive summary

• Achieved 21% year-over-year revenue growth in Q2 2026 to $8.2 million, driven by increased clinical adoption, higher instrument and consumable sales, and global expansion, especially in Europe.

• Consumables revenue rose 31% year-over-year, with a 27% increase in flow cell sales and strong demand from existing clinical customers.

• Leadership strengthened with the return of Dr. Alex Hastie as Chief Scientific Officer.

• Full retirement of all outstanding senior secured convertible debentures, simplifying the balance sheet.

• Installed base of OGM systems grew 5% year-over-year to 397 units as of June 30, 2026.

Financial highlights

• Q2 2026 revenue was $8.2 million, up 21% year-over-year and above guidance.

• Sold 9,219 nanochannel array flow cells, up 27% year-over-year, with demand outpacing supply.

• Consumable revenue reached $4.3 million (up 31% YoY), software revenue was $1.4 million (down 16% YoY), and other revenue was $2.5 million (up 38% YoY).

• Gross margin improved to 53% in Q2 2026, highest to date.

• Net loss for Q2 2026 was $7.4 million, compared to $6.9 million in Q2 2025.

Outlook and guidance

• Raised 2026 revenue guidance to $31–$33 million, representing 9–16% growth over 2025.

• Q3 2026 revenue guidance set at $8.2–$8.6 million, 11–16% growth over Q3 2025.

• Sequential Q3 growth expected to be modest due to timing of large orders and ongoing supply constraints.

• Management expects continued operating losses and negative cash flows for at least the next year.

• Current cash resources are expected to fund operations into at least Q1 2027.